ROS1-fusions occur in several cancer types- non-small cell lung cancer, gastric cancer, ovarian cancer, glioblastoma, cholangiocarcinoma, melanoma, and others. In each of these cancers, ROS1-fusions account for a small sliver of the pie, accounting for approximately 1-2% of all diagnoses, resulting in a relatively rare yet critically important molecular subset of cancer. The Addario Lung Cancer Medical Institute (ALCMI) is focusing efforts on this under-studied molecular subset of cancer to understand what drives tumor formation, therapeutic response, and acquired therapeutic resistance. Therefore, in support of cancer patients whose tumors have ROS1-fusions, we are launching a global effort to study ROS1-fusions across all tumor types.
Click on topic below for more information.